Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for Breast cancer and other Solid tumors. It is a dual tyrosine kinase inhibitor (Protein kinase inhibitor) which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways.
It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).
- Testican-1-mediated epithelial–mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer Oncogene : HER2+ Gastric cancer에서 Lapatinib resitance에 영향을 주는 요인은 Testican-1에 의한 Epithelial–mesenchymal transition